Apellis Announces Seven Abstracts in PNH to be Presented at the European Hematology Association Congress
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
targeting C3 offers the potential to provide comprehensive control of complement, a part of the immune system
Our Sciencetreatment across a broad range of debilitating diseases driven by complement
Pipeline